ArticleAmerican journal of respiratory and critical care medicine2026
Microbiome-targeted antibiotics provide no additional microbiologic or inflammatory benefit during cystic fibrosis pulmonary exacerbations: results from the CFMATTERS trial.
Gisli G Einarsson et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.